AI-powered trial matching helps identify relevant trials faster, but recruitment often fails beyond the algorithm. Limited cross-site trial discovery, outdated recruitment information and fragmented referral pathways continue to prevent potentially eligible patients from participating in relevant trials.
A new ESMO consensus-driven document provides definitions, formats and minimum required data to uniform enumeration and reporting of prior lines of therapy across solid tumours
COMPASS trial suggests that selecting treatment based on subtypes classification may impact patients’ outcomes, but the approach is hard to implement in clinical practice
Drug development in oncology is increasingly moving towards integrated strategies that consider tumour cells, their microenvironment and anatomical context
Despite advances in molecular profiling, only a small fraction of patients with actionable alterations receive matched targeted therapies or immunotherapies
Early findings suggest potential benefits in symptom monitoring, but highlight usability challenges and added burden on clinical workflows
Understanding the evolution of immunotherapy resistance holds the key to developing novel strategies in NSCLC
From chronotherapy to immunotherapy resistance, refining when and for whom treatments work is becoming central to making oncology sustainable
Recent data provide further evidence that non-risk-based screening can improve survival if biomarkers can be identified to target screening to those at the highest risk
Early phase III trial results signal a much-needed chemotherapy-free advance with gotistobart in a setting where therapeutic choices are limited
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.